Cover Image

Efficacy and Safety of Anti-TNF Biosimilars for Psoriasis in Pediatric and Geriatric Populations: A 72-Week Real-Life Study

Matteo Megna, Luigi Fornaro, Luca Potestio, Maria Antonietta Luciano, Mariateresa Nocerino, Mario Delfino, Maria Guarino, Gabriella Fabbrocini, Elisa Camela Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, NA, ItalyCorrespondence: Elisa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Megna M (Author), Fornaro L (Author), Potestio L (Author), Luciano MA (Author), Nocerino M (Author), Delfino M (Author), Guarino M (Author), Fabbrocini G (Author), Camela E (Author)
Format:	Book
Published:	Dove Medical Press, 2022-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
by: Ruggiero A, et al.
Published: (2022)

Treatment of pediatric psoriasis with TNF-antagonists: a real-life single-center case series
by: Matteo Megna, et al.
Published: (2022)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
by: Potestio L, et al.
Published: (2023)

Towards Personalized Medicine in Psoriasis: Current Progress
by: Camela E, et al.
Published: (2022)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
by: Megna M, et al.
Published: (2022)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
by: Ruggiero A, et al.
Published: (2023)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
by: Potestio L, et al.
Published: (2023)

Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
by: Megna M, et al.
Published: (2024)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
by: Megna M, et al.
Published: (2023)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
by: Potestio L, et al.
Published: (2023)

Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis
by: Rachel C. Ruda, et al.
Published: (2023)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
by: Martora F, et al.
Published: (2023)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022)

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
by: Martora F, et al.
Published: (2024)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
by: Claudia Fabiani, et al.
Published: (2019)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
by: Cacciapuoti S, et al.
Published: (2023)

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
by: Battista T, et al.
Published: (2023)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
by: Martora F, et al.
Published: (2023)

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
by: Ruggiero A, et al.
Published: (2022)

The effect of tildrakizumab on adipokines production in patients affected by psoriasis and obesity: preliminary results from a single center real-life study
by: Sara Cacciapuoti, et al.
Published: (2024)

The Role of Interleukin 23/17 Axis in Psoriasis Management: A Comprehensive Review of Clinical Trials
by: Potestio L, et al.
Published: (2024)

Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)
by: Diego Orsini, et al.
Published: (2024)

Injections Site Reactions and Biologics for Psoriasis: A Questionnaire Based Real Life Study
by: Matteo M, et al.
Published: (2023)

Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience
by: Martina Maurelli, et al.
Published: (2023)

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
by: Potestio L, et al.
Published: (2023)

Risk Factors for Psoriasis Flares: A Narrative Review
by: Potestio L, et al.
Published: (2024)

Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report
by: Martora F, et al.
Published: (2024)

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience-IL PSO (Italian Landscape Psoriasis)
by: Diego Orsini, et al.
Published: (2024)

Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
by: Zhen Zeng, et al.
Published: (2024)

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary
by: Arnon D. Cohen, MD, MPH, PhD, et al.
Published: (2020)

The effect of biosimilar administration on clinical outcomes in patients with adalimumab‐controlled psoriasis
by: M. Panahi, et al.
Published: (2021)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab [Corrigendum]
by: Megna M, et al.
Published: (2024)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
by: Changkun Li, et al.
Published: (2023)

Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
by: Elisa Camela, et al.
Published: (2023)

An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
by: D. P. Kamilova, et al.
Published: (2021)

Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities
by: Luca Potestio, et al.
Published: (2024)

A case of adult-onset facial cutaneous mastocytoma: clinical and dermoscopic findings
by: Matteo Megna, et al.
Published: (2022)

Real-World Experience of Bimekizumab in an Elderly Patients Cohort with Plaque-Type Psoriasis: A 24-Week Retrospective Study
by: Fratton Z, et al.
Published: (2024)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021)